Linsitinib (OSI-906)

目录号：S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂，在无细胞试验中IC50为35 nM；对InsR抑制作用适中，IC50为75 nM，对Abl，ALK，BTK，EGFR， FGFR1/2，PKA等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 1550.54 现货
RMB 1393.48 现货
RMB 2226.24 现货
RMB 5899.91 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck该产品发表文献33篇：

客户使用该产品的6个实验数据：

  • (e) c-peptide from these mice 240 min after respective treatments.

    Nature, 2018, 560(7719):499-503. Linsitinib (OSI-906) purchased from Selleck.

    Inhibition of IGF receptor by the IGFR inhibitor linsitinib reduced ERK1/2 signaling activation particularly in U87MG RG7388 resistant cells.

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1580. Linsitinib (OSI-906) purchased from Selleck.

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂，在无细胞试验中IC50为35 nM；对InsR抑制作用适中，IC50为75 nM，对Abl，ALK，BTK，EGFR， FGFR1/2，PKA等没有抑制活性。Phase 3。
靶点
IGF-1R [1]
(Cell-free assay)		 Insulin Receptor [1]
(Cell-free assay)		 IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活，IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体，具有良好的代谢稳定性。OSI-906浓度为1μM时，完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖，包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系，EC50为0.021到 0.810 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NFXwb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LK[WlEPTB;MD6wNlgxPiEQvF2= MUnTRW5ITVJ?
KS-1 MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHqSXMxUUN3ME2wMlA{QDN3IN88US=> M17tPXNCVkeHUh?=
TE-11 M{L6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fSVGlEPTB;MD6wO|gzOiEQvF2= MUHTRW5ITVJ?
EW-1 M3PHN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMEi1PFUh|ryP MYXTRW5ITVJ?
HMV-II Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET4U2tKSzVyPUCuNFg5PDZizszN NV;GT3J{W0GQR1XS
COLO-205 MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvR[oRKSzVyPUCuNVA1PTRizszN MomyV2FPT0WU
ES1 NH;Uc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLEfZpCUUN3ME2wMlExPjl4IN88US=> MY\TRW5ITVJ?
GDM-1 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnTXFFCUUN3ME2wMlE{Pjd{IN88US=> NYH2bolxW0GQR1XS
ML-2 M2jETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j4cGlEPTB;MD6xOVg6PiEQvF2= MljIV2FPT0WU
Saos-2 NH35RXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjU[os2UUN3ME2wMlE3PTJ4IN88US=> MUHTRW5ITVJ?
NCI-H1355 MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrwVXJKSzVyPUCuNVgyOzVizszN NEjtTGFUSU6JRWK=
G-401 NGHPNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESwSWNKSzVyPUCuNVgzOyEQvF2= NF\BemVUSU6JRWK=
EW-16 NIezVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PDb2lEPTB;MD6xPFc4PyEQvF2= M3nCb3NCVkeHUh?=
EW-7 NYTvc5V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzwdoJuUUN3ME2wMlE5QDhzIN88US=> NHf0Oo1USU6JRWK=
NCI-H727 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\1TWM2OD1yLkG5O|k1KM7:TR?= Mn;iV2FPT0WU
LCLC-97TM1 NXnyXpE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMkC5OVUh|ryP NIPufXhUSU6JRWK=
NCI-H650 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMkGzPFQh|ryP M3z2WnNCVkeHUh?=
NCI-H2122 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHTfVZKSzVyPUCuNlMzQTlizszN NH21T3VUSU6JRWK=
SK-N-DZ NYrGVYVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\lXWlEPTB;MD6yN|Y6QCEQvF2= MoTXV2FPT0WU
HT-29 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfNUHpCUUN3ME2wMlI1OjR6IN88US=> M4PX[nNCVkeHUh?=
LB771-HNC M3G0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLoTWM2OD1yLkK1PVE2KM7:TR?= NXLsN4k5W0GQR1XS
HT-144 NGPub4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMk[xPVEh|ryP NHTMRmRUSU6JRWK=
LAN-6 MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfmfpZmUUN3ME2wMlI3OzR6IN88US=> NGXpR4JUSU6JRWK=
EW-18 NWjLdVBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\3TYVZUUN3ME2wMlI4ODBzIN88US=> MlHYV2FPT0WU
LS-1034 Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jWUWlEPTB;MD6yO|E{OiEQvF2= MnXIV2FPT0WU
EW-11 NXjqdGhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XHbWlEPTB;MD6yPFQ{OiEQvF2= M4HQRnNCVkeHUh?=
SNU-C1 NF\oT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT3TWM2OD1yLkK5N|E{KM7:TR?= MnTIV2FPT0WU
RS4-11 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G0O2lEPTB;MD6zN|c2QCEQvF2= M2\JbnNCVkeHUh?=
ES4 Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwNEGwN|gh|ryP M{D3O3NCVkeHUh?=
COLO-320-HSR M3;4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHzTnRKSzVyPUCuOFE{PjhizszN NH\CbZNUSU6JRWK=
NB10 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LiTmlEPTB;MD60OVQ{PyEQvF2= MV;TRW5ITVJ?
BFTC-905 M13RZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwNE[3OVgh|ryP MVXTRW5ITVJ?
A375 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwNEe2NVch|ryP M1rwVHNCVkeHUh?=
SJRH30 NEfiVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwNUC4NlIh|ryP NX;QZphXW0GQR1XS
NOS-1 NI\TXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwNUKyOlch|ryP NHLHXIpUSU6JRWK=
SIG-M5 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fVcGlEPTB;MD61N|U2PyEQvF2= MVvTRW5ITVJ?
DOK Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXhc4FKSzVyPUCuOVU3KM7:TR?= MknCV2FPT0WU
NB69 NXrMO4FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwNUiyOVch|ryP NIjoOHlUSU6JRWK=
SK-NEP-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml73TWM2OD1yLk[wNlM3KM7:TR?= NF3vVGtUSU6JRWK=
SK-MM-2 M1rSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXQTWM2OD1yLk[1OFkyKM7:TR?= M2fCSnNCVkeHUh?=
NCI-H358 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfNN5RjUUN3ME2wMlY4ODh{IN88US=> Ml[zV2FPT0WU
RH-1 NIfnNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwN{S4OVkh|ryP M1rRenNCVkeHUh?=
NH-12 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfCU|lZUUN3ME2wMlc3ODR4IN88US=> MUPTRW5ITVJ?
TE-12 NVzGbIRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjlS|kyUUN3ME2wMlc3PDh4IN88US=> NGXNSmdUSU6JRWK=
COLO-668 NHuycm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwOES2OlYh|ryP NH7OWYRUSU6JRWK=
PANC-08-13 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLrVm5mUUN3ME2wMlg3Ozd5IN88US=> MljDV2FPT0WU
HCC2998 NVHiT5hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfHVW1KSzVyPUCuPFgzPjNizszN NXjz[VBDW0GQR1XS
ABC-1 NXzwWWZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n6b2lEPTB;MD65NFM2OiEQvF2= MUjTRW5ITVJ?
ES6 NHnWSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDmZ5FPUUN3ME2wMlkyODZ4IN88US=> NEfKWJRUSU6JRWK=
SNU-387 M{nKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i2SGlEPTB;MD65PVM6OyEQvF2= MnzvV2FPT0WU
CMK Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\nTWM2OD1yLkm5PVI6KM7:TR?= NEPGS|lUSU6JRWK=
SJSA-1 NFrmZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwMEO2OVMh|ryP NXzYOGliW0GQR1XS
SIMA M{DxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwME[4NlUh|ryP MXPTRW5ITVJ?
ES3 NHjpXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjWepVKSzVyPUGuNVIzQTdizszN NHX1[IdUSU6JRWK=
IGROV-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjKUppKSzVyPUGuNVU1PDRizszN MXLTRW5ITVJ?
MEL-JUSO NYDyWYpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PVUWlEPTB;MT6xOVc2QSEQvF2= NF;TcZNUSU6JRWK=
T84 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r4OmlEPTB;MT6yNFkyPCEQvF2= MmnTV2FPT0WU
CAL-85-1 NWTxVZM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX4S|dKSzVyPUGuNlMyOzhizszN Ml3jV2FPT0WU
RD MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDnUmR4UUN3ME2xMlI3PDV3IN88US=> MX\TRW5ITVJ?
TE-8 NH3KN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf6RnR[UUN3ME2xMlMyPDZ{IN88US=> Ml2yV2FPT0WU
L-363 M2nGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwM{SyNFgh|ryP MXTTRW5ITVJ?
EKVX MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\Ne5NKSzVyPUGuN|Q2PjhizszN NY\acZdCW0GQR1XS
SK-MEL-3 M1nR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwNEi1OVYh|ryP MojpV2FPT0WU
TGBC24TKB M3rwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK4cIhEUUN3ME2xMlUxOTl|IN88US=> NX\mOHN6W0GQR1XS
NCI-H1770 NV3KNXpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnlUlR4UUN3ME2xMlUyOTF|IN88US=> MV\TRW5ITVJ?
HuH-7 NYjDbJlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jHZWlEPTB;MT62NFA6QCEQvF2= NHrJPHRUSU6JRWK=
HL-60 M2PkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDRU5BPUUN3ME2xMlY3QTJ6IN88US=> NWDrdG5NW0GQR1XS
TE-1 NHjIc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjab4dZUUN3ME2xMlcxQTR3IN88US=> M4DVVXNCVkeHUh?=
LC-2-ad MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrlR2Y4UUN3ME2xMlc{QDh5IN88US=> NF3qPYpUSU6JRWK=
LB647-SCLC M{W3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjoSHZKSzVyPUGuO|Y2QDNizszN MnzIV2FPT0WU
NCI-H2171 NHe3UpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwN{e3NVYh|ryP NYCx[FR4W0GQR1XS
SK-PN-DW NEjy[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1WxVWlEPTB;MT65NVI6QCEQvF2= Mkf1V2FPT0WU
MC-IXC NVv5RW1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rKPWlEPTB;MT65PFk5KM7:TR?= Ml\hV2FPT0WU
LS-513 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3USlllUUN3ME2yMlA2OzB3IN88US=> NYL5XHdlW0GQR1XS
EW-3 NVWz[pF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv1ZodKSzVyPUKuNFk5PDRizszN Ml;JV2FPT0WU
OPM-2 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUix[mtjUUN3ME2yMlExOiEQvF2= MXjTRW5ITVJ?
LP-1 M1HQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTPTWM2OD1{LkK1PFA4KM7:TR?= Ml3kV2FPT0WU
LU-134-A NF7D[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDub2hxUUN3ME2yMlI4PyEQvF2= MVHTRW5ITVJ?
CP66-MEL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jycmlEPTB;Mj6yPVAyPCEQvF2= MoTqV2FPT0WU
HCC1143 M2rzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwNEWzOlgh|ryP NIr5XItUSU6JRWK=
LOXIMVI M2rBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL4TWM2OD1{Lk[wNlEh|ryP NWn6V2ZCW0GQR1XS
TE-10 NHvBZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfIOnl3UUN3ME2yMlcxQDN6IN88US=> M{L2OHNCVkeHUh?=
NCI-H1882 NGTnfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHuTWM2OD1{Lke1NlI4KM7:TR?= MWjTRW5ITVJ?
CHP-126 M1frOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TxUmlEPTB;Mj63OlMyPyEQvF2= M4f6dnNCVkeHUh?=
NCI-H1623 M1HPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\1cGlEPTB;Mj65NlAzPCEQvF2= Mn7IV2FPT0WU
GB-1 MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\SR2lEPTB;Mj65N|QxPCEQvF2= NUH5VpFFW0GQR1XS
RCC10RGB M{O5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTOVWZKSzVyPUKuPVUzQDFizszN NWTXS5NvW0GQR1XS
NCI-H2141 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu3TWM2OD1{Lkm2PFk3KM7:TR?= MkPHV2FPT0WU
GI-ME-N NVr1PFd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjydI9jUUN3ME2zMlAxPTZ3IN88US=> NFPZOHVUSU6JRWK=
NCI-H526 NYXQN2s2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHoNnBKSzVyPUOuNFQxQDVizszN NFLFd|NUSU6JRWK=
NCI-H747 NUSxR2JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fYVmlEPTB;Mz6wOFk6OiEQvF2= NXHKcnR3W0GQR1XS
SNU-423 M1zqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNwMkCzNVMh|ryP NH;r[|NUSU6JRWK=
A427 NEjvWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTNwMkW2PVkh|ryP MYnTRW5ITVJ?
CAL-12T M2nBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LFVWlEPTB;Mz60NFcyOyEQvF2= MkHMV2FPT0WU
LU-99A NWfzZm5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHlNllKSzVyPUOuOFcyODVizszN M4[5WHNCVkeHUh?=
MS-1 M3y5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDoTWM2OD1|LkWzOFI6KM7:TR?= MV7TRW5ITVJ?
SK-LU-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfkbWRtUUN3ME2zMlc3Ojl3IN88US=> M3\OdHNCVkeHUh?=
SW837 NIjp[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[wcppKSzVyPUOuO|Y{OzNizszN MYDTRW5ITVJ?
ES8 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPJfXFwUUN3ME2zMlg{QDd5IN88US=> NXXJRXl5W0GQR1XS
MZ2-MEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvoT4VKSzVyPUOuPVIxQDZizszN MlPpV2FPT0WU
TGW MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTRwMEGzNVEh|ryP NXvDd3RQW0GQR1XS
GP5d M4j2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLtU5VKSzVyPUSuNFU{PjJizszN M3zvZnNCVkeHUh?=
BB49-HNC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTRwMUWyNVMh|ryP NFXQVIJUSU6JRWK=
NB13 M{nkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTRwMk[4PFch|ryP M{nVfHNCVkeHUh?=
NTERA-S-cl-D1 NVvWWIN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjGXW1KSzVyPUSuNlg3OTVizszN M4DtRXNCVkeHUh?=
NCI-H1648 NEHBZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fKeWlEPTB;ND6yPVgyQSEQvF2= MXXTRW5ITVJ?
LCLC-103H MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrTTWM2OD12LkOyNVk2KM7:TR?= MX\TRW5ITVJ?
LS-411N NIHmdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;uTWM2OD12LkS0PFg2KM7:TR?= MUTTRW5ITVJ?
NCI-H1092 MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPRe3BEUUN3ME20MlQ2Pjh5IN88US=> MXzTRW5ITVJ?
PANC-10-05 NILRbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPoTWM2OD12Lk[5PFQh|ryP MoHtV2FPT0WU
DK-MG M1HSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHBTWM2OD12LkiwPVM{KM7:TR?= NE\oVG1USU6JRWK=
OVCAR-5 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfTfo5MUUN3ME20MlgyOjJ4IN88US=> M2CwXXNCVkeHUh?=
CAL-39 M3m0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlmxTWM2OD12Lki3Olch|ryP MXXTRW5ITVJ?
TE-441-T M17zS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILsNVBKSzVyPUSuPVA2OzdizszN NXLicGt4W0GQR1XS
MOLT-16 NVXx[W96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED5dHJKSzVyPUSuPVUzPTNizszN MXTTRW5ITVJ?
MCF7 NH7ZNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nSRmlEPTB;NT6xOFUyPyEQvF2= MkjRV2FPT0WU
CAPAN-1 NHHDeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjv[|lKSzVyPUWuNlU4ODdizszN MnfnV2FPT0WU
PSN1 M4i1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnnOJhpUUN3ME21MlI4OjN3IN88US=> NFH2OoFUSU6JRWK=
NCI-H292 NYLzUWtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr2OVdnUUN3ME21MlMxODR2IN88US=> NVrGdGZLW0GQR1XS
CPC-N NIrDbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1exdmlEPTB;NT6zPVQyQSEQvF2= NYfP[mR6W0GQR1XS
DoTc2-4510 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3naSmlEPTB;NT60OVM4OSEQvF2= M3;yWXNCVkeHUh?=
LB1047-RCC NFLT[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\mTWM2OD13LkW1PVM{KM7:TR?= NEDKOmpUSU6JRWK=
MHH-ES-1 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDkNYZEUUN3ME21MlU6QTB5IN88US=> NHywcmJUSU6JRWK=
NMC-G1 M2f2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj6U|lKSzVyPUWuO|AzOjdizszN M{nzNXNCVkeHUh?=
SW1710 M1rFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHGTWM2OD13Lke0O|UyKM7:TR?= NWTQOWE2W0GQR1XS
YAPC NYjFNphmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm1W|FIUUN3ME21Mlc3OjBzIN88US=> MUXTRW5ITVJ?
22RV1 NHj2b4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7aTWM2OD13LkiwNFE6KM7:TR?= MmO5V2FPT0WU
COLO-679 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTVwOEi5OFgh|ryP MXLTRW5ITVJ?
TCCSUP NV;q[pEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\PZ2lEPTB;NT65N|I2QSEQvF2= NG\UZVBUSU6JRWK=
C2BBe1 NGPwenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTOTWM2OD13LkmzPVch|ryP NIfMWIJUSU6JRWK=
TE-15 NYnHdZdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK2TWM2OD14LkC2OlA2KM7:TR?= NUjqPZdoW0GQR1XS
SCLC-21H Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\mTWM2OD14LkGwPFQ{KM7:TR?= NX\2Z3dHW0GQR1XS
EoL-1-cell NEPV[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrXZ4tCUUN3ME22MlE3PTZ|IN88US=> M{O3bXNCVkeHUh?=
NKM-1 M33vWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zybWlEPTB;Nj6xOlcyKM7:TR?= NIHB[nZUSU6JRWK=
NCI-H1304 NU\mTGxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZwMke0Nlgh|ryP M1XVTXNCVkeHUh?=
NB6 NX\zfXcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\JTI16UUN3ME22MlI6PjJ{IN88US=> MUfTRW5ITVJ?
NALM-6 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTZwM{OyN{DPxE1? NG\JXZRUSU6JRWK=
NCI-H522 M4HjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTZwM{OzNFYh|ryP NIDTPYZUSU6JRWK=
MV-4-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fMU2lEPTB;Nj6zO|A4QSEQvF2= NVq4RWJXW0GQR1XS
LB2241-RCC M1S0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHxNVFKSzVyPU[uN|g3PjdizszN NU\WcHhnW0GQR1XS
NCI-H1417 NXrifItbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS4N5FKSzVyPU[uOFA5PDdizszN NVz1VZpWW0GQR1XS
HT-1197 NES1e2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvvVZVKSzVyPU[uOVcyOjJizszN NIPVfIVUSU6JRWK=
P30-OHK MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XT[mlEPTB;Nj62Nlc4KM7:TR?= NVL4UmpZW0GQR1XS
ALL-PO NETLempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTZwN{G5NVYh|ryP NETscopUSU6JRWK=
OVCAR-4 MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3xTWM2OD14Lke1OFA2KM7:TR?= NVq1TYloW0GQR1XS
HCC2157 Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\5fpdKSzVyPU[uO|c1PzVizszN MX;TRW5ITVJ?
NCI-H838 NIDWfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknRTWM2OD14Lkm2OFkh|ryP MUjTRW5ITVJ?
NCI-H1299 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf5b4tNUUN3ME22Mlk4ODlizszN MlnKV2FPT0WU
SW954 M4Pmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvJRoFKUUN3ME23MlIxODZ6IN88US=> MYDTRW5ITVJ?
NCI-H441 NEHsWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nqcWlEPTB;Nz6zOFA3PSEQvF2= MmXUV2FPT0WU
SK-MEL-2 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD4e3d7UUN3ME23MlQ5Ozd|IN88US=> MVzTRW5ITVJ?
KARPAS-45 M1PWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XRcWlEPTB;Nz62OVkzQSEQvF2= MWPTRW5ITVJ?
CAL-54 Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKxOohKSzVyPUeuPFI6PzdizszN NWjkc5J6W0GQR1XS
KYSE-180 M3q3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTMPVc3UUN3ME23Mlg5QTRzIN88US=> MWDTRW5ITVJ?
NCI-H187 NH34ZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW2UHBYUUN3ME23Mlk2QTR5IN88US=> MYHTRW5ITVJ?
RT-112 M{HJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr4SWdKSzVyPUiuNFk3PzdizszN MkLSV2FPT0WU
NCI-H1437 NEntOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XXVWlEPTB;OD6wPVc6PSEQvF2= MorTV2FPT0WU
SNU-449 M2nKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jZWWlEPTB;OD6yPFI4OiEQvF2= NGLudVVUSU6JRWK=
HCC1187 MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33OdGlEPTB;OD6yPVM6OSEQvF2= MkXpV2FPT0WU
NCI-H2030 NWr5cpR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUCxSWI4UUN3ME24MlM4PzF2IN88US=> NFvTW|JUSU6JRWK=
HuO-3N1 NVyycld3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRThwM{e4OFQh|ryP NV;M[49{W0GQR1XS
COLO-792 NGrFe21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\STWM2OD16LkSxOVI4KM7:TR?= Mo\jV2FPT0WU
MIA-PaCa-2 MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRThwOEW1NFgh|ryP MX\TRW5ITVJ?
SK-N-FI MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P2fmlEPTB;OT6wOFI2KM7:TR?= NIrnWGRUSU6JRWK=
MMAC-SF NEjYWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTlwMEm3OVEh|ryP NYXPNWREW0GQR1XS
NCI-H28 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K1UmlEPTB;OT6xNFQ3QSEQvF2= Mk[zV2FPT0WU
ETK-1 Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHXbWJKSzVyPUmuNlk6PzRizszN MoSwV2FPT0WU
NCI-H1993 M{\QN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTjXYZnUUN3ME25MlQ1OjZzIN88US=> MlGyV2FPT0WU
no-11 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTlwNEexNkDPxE1? NWDoTYJiW0GQR1XS
ChaGo-K-1 M2mwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv1PYFSUUN3ME25MlUyPTh|IN88US=> NF7NZnRUSU6JRWK=
NCCIT NYHScI06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DCT2lEPTB;OT61N|E3QSEQvF2= NHW1RYhUSU6JRWK=
SAS NEPZPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;NN3BKUUN3ME2xNE4zPDhizszN NEPwVHNUSU6JRWK=
A673 M3XtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3rb2JKSzVyPUGwMlM4ODRizszN NWnBTHlNW0GQR1XS
NCI-H1522 M1rPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPSTWM2OD1zMD6zO|A4KM7:TR?= NE\iS2tUSU6JRWK=
NCI-H810 M3LqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DSV2lEPTB;MUCuN|kxPyEQvF2= MYHTRW5ITVJ?
IST-MES1 NGPXOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFyLkS1OlQh|ryP MkPUV2FPT0WU
GR-ST MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFyLkWwNlQh|ryP NYnYNYNmW0GQR1XS
SUP-T1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLKUG1rUUN3ME2xNE44OzF5IN88US=> MYLTRW5ITVJ?
NB5 NX7rTI9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonJTWM2OD1zMD65NFIzKM7:TR?= MmXVV2FPT0WU
MZ1-PC MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzOVWdKSzVyPUGwMlk2PzFizszN MWjTRW5ITVJ?
SK-CO-1 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFyLkm5N|Eh|ryP MYDTRW5ITVJ?
Capan-2 NYfnOG1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFzLkOxPVgh|ryP NVvXXHNTW0GQR1XS
697 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfWZpdKSzVyPUGxMlY4PTdizszN M3fxUXNCVkeHUh?=
REH NFHiVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XpU2lEPTB;MUGuO|Q2OSEQvF2= MYrTRW5ITVJ?
GI-1 NFnSS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\mUlY1UUN3ME2xNU45PjF3IN88US=> MkfxV2FPT0WU
BB65-RCC NYLlSJY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nvVWlEPTB;MUKuNFkyPiEQvF2= M13sRXNCVkeHUh?=
NCI-H1651 NFjOXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF{LkK0O|gh|ryP MnztV2FPT0WU
NCI-H1618 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\aN|NKSzVyPUGyMlM6PzZizszN MVPTRW5ITVJ?
NCI-H2081 NF3NeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13QcmlEPTB;MUKuOlE1OSEQvF2= M4HVSHNCVkeHUh?=
GCIY MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1WxcGlEPTB;MUKuO|IyOyEQvF2= Moq1V2FPT0WU
NY NGezc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF|LkC2OFMh|ryP MnPYV2FPT0WU
PANC-03-27 M3nSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF|LkC4NFch|ryP MmD2V2FPT0WU
BHY M4D1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj4PZJKSzVyPUGzMlIyOjFizszN NWDCW4ptW0GQR1XS
SK-OV-3 NYT3epA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX1TWM2OD1zMz6zO|Y{KM7:TR?= Mn\iV2FPT0WU
5637 NHq2UYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF|Lke3OVkh|ryP M{jTSXNCVkeHUh?=
LC-1F MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFexN41KSzVyPUG0MlA{PTZizszN MXnTRW5ITVJ?
SNB75 M1vTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF2LkCzPFMh|ryP MkH6V2FPT0WU
CHP-212 M{TrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF2LkC0OlQh|ryP NYnWb3dIW0GQR1XS
HT-1376 NGixZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXOTWM2OD1zND6xNVI3KM7:TR?= NGT1UYNUSU6JRWK=
MONO-MAC-6 NYXvVG92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PpRWlEPTB;MUSuNVUxOiEQvF2= NYTPfox7W0GQR1XS
CA46 M2\ifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX0c2xKSzVyPUG0MlE5OjdizszN NHniXHdUSU6JRWK=
SCC-15 M2PZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPJdVAyUUN3ME2xOE42PTh|IN88US=> NHXRS25USU6JRWK=
ATN-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF2Lk[2Nlch|ryP M1jDVHNCVkeHUh?=
NCI-H2405 NIPXfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF2LkixOVch|ryP MnfCV2FPT0WU
NCI-H716 NIjqTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISx[GxKSzVyPUG0Mlg1QTNizszN MYPTRW5ITVJ?
SW620 NIP3S3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zr[mlEPTB;MUSuPVAyPCEQvF2= NVz3Z49NW0GQR1XS
NCI-H226 MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF2LkmwPFUh|ryP M3PLS3NCVkeHUh?=
SW962 MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKxSWNKSzVyPUG0Mlk1OzJizszN NVTvPJoxW0GQR1XS
KYSE-150 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofpTWM2OD1zND65OVUh|ryP MkPYV2FPT0WU
OCUB-M NF;MWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF2Lkm4PFMh|ryP M3faOHNCVkeHUh?=
ES7 M1PONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHSbo1CUUN3ME2xOU4xQTh2IN88US=> M1rSeHNCVkeHUh?=
SW1463 M2[4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nyfGlEPTB;MUWuOFIzOyEQvF2= MWPTRW5ITVJ?
CAKI-1 NXrlRY01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zINGlEPTB;MUWuOVM1PiEQvF2= M{DlR3NCVkeHUh?=
MKN28 M{PE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknaTWM2OD1zNT61OFc6KM7:TR?= Mmn4V2FPT0WU
SW13 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17LT2lEPTB;MUWuOlE5KM7:TR?= M4nlVXNCVkeHUh?=
A3-KAW MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPsfnNKSzVyPUG1Mlk3QTdizszN NFTlfGxUSU6JRWK=
LU-65 M3rtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELocIxKSzVyPUG1Mlk4PjhizszN NGDEPYlUSU6JRWK=
Calu-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvTS|dKSzVyPUG2MlA{PjhizszN NF\aSYJUSU6JRWK=
ST486 M{XCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGCyOWNKSzVyPUG2MlA1OzFizszN M1i2bXNCVkeHUh?=
BB30-HNC NG\3NWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF4LkGyOFYh|ryP NGjwTZFUSU6JRWK=
EGI-1 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M375cmlEPTB;MU[uOFQ3KM7:TR?= MUjTRW5ITVJ?
SH-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF4LkS3N|Eh|ryP M3HYVHNCVkeHUh?=
MN-60 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF5LkKyPVch|ryP NXjFcFhoW0GQR1XS
MPP-89 NY[5XWR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF5LkK0OVkh|ryP MoHnV2FPT0WU
A2780 NF61eoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf1N3JKSzVyPUG3MlQyOzlizszN NETqdlVUSU6JRWK=
Daoy NWHLNXc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LTV2lEPTB;MUeuOFY6PSEQvF2= NGTIdZZUSU6JRWK=
NCI-H2126 M2rVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDqNFNKSzVyPUG3MlQ4PzFizszN MVjTRW5ITVJ?
NCI-H1563 NFHZPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF5LkS5NVch|ryP M3y4VXNCVkeHUh?=
8-MG-BA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfFSmhKSzVyPUG3MlY3PDhizszN MX7TRW5ITVJ?
786-0 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;x[IZKSzVyPUG3Mlg{PTNizszN M{HkUXNCVkeHUh?=
AM-38 NILTdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfo[ppKSzVyPUG3Mlk{ODZizszN MV;TRW5ITVJ?
COLO-824 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITySGhKSzVyPUG4MlQ1OzZizszN NH;5ZZpUSU6JRWK=
SK-MEL-30 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\DTWM2OD1zOD61NFgzKM7:TR?= NIX5bpJUSU6JRWK=
CESS NVLEZ5lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm2Wox7UUN3ME2xPE44PjB7IN88US=> NYPVOGpDW0GQR1XS
BL-70 NXPoVY5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHyfG1KSzVyPUG4MlgyPTZizszN MlKxV2FPT0WU
NCI-H2170 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF6LkmxO|kh|ryP M4DhPXNCVkeHUh?=
HT-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrMeo1HUUN3ME2xPE46QDNizszN NEL6PHlUSU6JRWK=
BOKU M2P3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[5dmN[UUN3ME2xPU4xOzhzIN88US=> NVr2XFFbW0GQR1XS
HPAF-II MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjZTnpKSzVyPUG5MlMxOTVizszN M4WxZnNCVkeHUh?=
KGN M4X2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF7LkS3OlUh|ryP M2LXUnNCVkeHUh?=
MC-CAR NUnLZYp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuy[3A2UUN3ME2xPU43OzF|IN88US=> M2DMPXNCVkeHUh?=
BHT-101 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDGOIdKSzVyPUG5Mlc4PyEQvF2= MnrYV2FPT0WU
SW1783 Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r1SGlEPTB;MUmuO|gxPiEQvF2= NHPVd|lUSU6JRWK=
KP-N-YN NHXjU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37yV2lEPTB;MkCuNFI3OiEQvF2= MWHTRW5ITVJ?
LU-165 NX\RfWZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;He4ljUUN3ME2yNE42PTdzIN88US=> M3vmOHNCVkeHUh?=
GOTO NYfvXnFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLrUnlHUUN3ME2yNE43PDVzIN88US=> NULqTGxjW0GQR1XS
EFM-19 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJzLkC3NVYh|ryP NYrHdI9YW0GQR1XS
CTV-1 NGHaWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDDS4NCUUN3ME2yNU4yODV2IN88US=> MkLFV2FPT0WU
HEL MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJzLkSyNVYh|ryP M4HP[nNCVkeHUh?=
SNU-C2B NHf2VYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXWeXBKSzVyPUKxMlQzPiEQvF2= NFjqWFNUSU6JRWK=
ECC4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfPRYtKSzVyPUKxMlcxPyEQvF2= MmTTV2FPT0WU
NEC8 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj1TWM2OD1{MT64N|Y5KM7:TR?= M1q2Z3NCVkeHUh?=
KMOE-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3MTWM2OD1{MT64PVIyKM7:TR?= MUnTRW5ITVJ?
NCI-H524 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvneZJvUUN3ME2yNk4xQDB6IN88US=> MVvTRW5ITVJ?
WSU-NHL NHnXWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jYU2lEPTB;MkKuNVU4PyEQvF2= M3LmNXNCVkeHUh?=
SF126 NIDQcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJ{LkK0Olkh|ryP MVnTRW5ITVJ?
HOP-92 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfoTWM2OD1{Mj6zNVY4KM7:TR?= M161RXNCVkeHUh?=
CTB-1 NISxN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7vPFh5UUN3ME2yNk41Pjd5IN88US=> NV3hTVdIW0GQR1XS
KYSE-270 M3e1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHqdIdKSzVyPUKyMlk{PTdizszN NGCyeFBUSU6JRWK=
SK-MEL-24 NEXSb|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJ|LkG4O{DPxE1? MYHTRW5ITVJ?
Calu-3 NVXrUVJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXRR5RKSzVyPUKzMlIyOjhizszN NYjjcXl1W0GQR1XS
GAMG MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTJ|LkKzOlch|ryP NYfkO3lkW0GQR1XS
SW1573 NIruOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fRTGlEPTB;MkOuO|QyPSEQvF2= MmrsV2FPT0WU
MHH-NB-11 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4SxW2lEPTB;MkSuNFE6PCEQvF2= NXH3N5RmW0GQR1XS
TK10 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJ2LkWwNVMh|ryP NVfk[4NpW0GQR1XS
LB373-MEL-D M1K1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTwTWM2OD1{ND62NFY1KM7:TR?= M2Cwe3NCVkeHUh?=
KALS-1 M176SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrKTWM2OD1{ND63N|I4KM7:TR?= MYnTRW5ITVJ?
HUTU-80 M33rVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ3LkiwN|Ih|ryP MmTCV2FPT0WU
HuP-T3 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jTc2lEPTB;Mk[uNVY4PCEQvF2= NEnCeYdUSU6JRWK=
OE19 M2HEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHtVZRHUUN3ME2yOk4zOTV|IN88US=> M{jS[3NCVkeHUh?=
J82 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPrc4JyUUN3ME2yOk4zPDdzIN88US=> MWTTRW5ITVJ?
DU-4475 M2X6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjkTWM2OD1{Nj6zPFE6KM7:TR?= NGj3[3dUSU6JRWK=
DMS-53 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWSy[5FvUUN3ME2yOk42OTN6IN88US=> Mlm5V2FPT0WU
COLO-741 M{XnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjpbohKSzVyPUK2Mlg{PDRizszN M3rJZnNCVkeHUh?=
SW48 NH;S[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\LTWM2OD1{Nj64PFIh|ryP M2e2dnNCVkeHUh?=
IGR-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XBemlEPTB;Mk[uPVM{PCEQvF2= NHzuVXVUSU6JRWK=
639-V NE\XWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ5LkCyOFUh|ryP NH7Xd45USU6JRWK=
LK-2 NVjBbHRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ5LkSxOFEh|ryP M3fXfnNCVkeHUh?=
NCI-H2347 NGHiUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnjSWI{UUN3ME2yO{46Pjl7IN88US=> MlS3V2FPT0WU
NCI-H2228 M{\0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3JSXVPUUN3ME2yPE4xQTB3IN88US=> M2nJWHNCVkeHUh?=
LS-123 M3Wxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJ6LkGyOlIh|ryP MlWxV2FPT0WU
U031 NH\5TppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC0cphsUUN3ME2yPE4zPTJizszN NUnxSolYW0GQR1XS
NCI-H1792 NHzsOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITRXpVKSzVyPUK4MlQ4OjFizszN NYTUcJRZW0GQR1XS
NCI-H2087 NXK3NpdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TocWlEPTB;MkiuO|U2OiEQvF2= M4HPRXNCVkeHUh?=
NCI-H2342 NXXMe2NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LaV2lEPTB;MkmuOVIxQCEQvF2= Mmn4V2FPT0WU
SW626 NWHGN4FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrwTWM2OD1{OT63OVYh|ryP NVvUV3FGW0GQR1XS
LB2518-MEL M1TsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ7LkixOUDPxE1? M3\sPXNCVkeHUh?=
RXF393 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vxcWlEPTB;M{CuNFk2OiEQvF2= MWXTRW5ITVJ?
LC4-1 NWnnU2JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f2c2lEPTB;M{CuN|A6OiEQvF2= M4rKPXNCVkeHUh?=
NCI-H1694 NUfSWm0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHQdHJKSzVyPUOwMlY3OjRizszN MoS5V2FPT0WU
K5 NWLuPXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW3b4NGUUN3ME2zNE46PzB{IN88US=> MoPjV2FPT0WU
HDLM-2 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNyLkm3NlUh|ryP M{\BR3NCVkeHUh?=
BCPAP M372TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jwPWlEPTB;M{GuPFM4QSEQvF2= MU\TRW5ITVJ?
BC-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXaTWM2OD1|Mj6xOFA{KM7:TR?= M4XQTnNCVkeHUh?=
LB996-RCC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnh[ZBxUUN3ME2zNk4zOzV6IN88US=> M3TIWnNCVkeHUh?=
NCI-H2009 NFvFRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTN{LkS5PFEh|ryP M4XyPHNCVkeHUh?=
HTC-C3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HJUWlEPTB;M{OuO|UyQSEQvF2= MlT6V2FPT0WU
LAMA-84 M3jHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjMTWM2OD1|ND60OFA4KM7:TR?= MmfaV2FPT0WU
CCRF-CEM MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS4PHpKSzVyPUO0MlU4OTVizszN Mn;5V2FPT0WU
AN3-CA NWLDXHpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTN3LkC1Olgh|ryP MXzTRW5ITVJ?
NCI-H1734 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjObIxKSzVyPUO1MlI2PjFizszN M3WzdXNCVkeHUh?=
Ca-Ski MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnmUoZTUUN3ME2zOU41OTBzIN88US=> NUfIbll5W0GQR1XS
U-266 NYn5bHFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjkdHp6UUN3ME2zOU43OTF2IN88US=> NIO3[lNUSU6JRWK=
SBC-5 NGfaT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7rTWM2OD1|NT63O|gyKM7:TR?= NVTKSY9NW0GQR1XS
GT3TKB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\oOINMUUN3ME2zO{4yOTVizszN NInGSm9USU6JRWK=
MDA-MB-175-VII MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCxR5ZKSzVyPUO3MlIzPDhizszN M{THe3NCVkeHUh?=
PFSK-1 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3YTWM2OD1|Nz6yOFM2KM7:TR?= M4r1RnNCVkeHUh?=
IMR-5 MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETtWGtKSzVyPUO3MlI1QDdizszN NWPMdIhrW0GQR1XS
Daudi NFzBfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTN5LkO1PVch|ryP M3zyN3NCVkeHUh?=
A498 M3\3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTzd3hFUUN3ME2zO{44OjF6IN88US=> MYHTRW5ITVJ?
SCC-4 NXf3fnF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH0TWM2OD1|Nz63PFQ{KM7:TR?= M2L2N3NCVkeHUh?=
COLO-680N MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnriTWM2OD1|OD6yPFg2KM7:TR?= M{HsdXNCVkeHUh?=
SK-MES-1 NV72[nBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTN6LkOyNVUh|ryP M1XPSnNCVkeHUh?=
SR M{\GR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEftVIRKSzVyPUO4MlU1QTVizszN NH7B[XBUSU6JRWK=
LNCaP-Clone-FGC MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTMNohRUUN3ME2zPE42PjN5IN88US=> M{jKOHNCVkeHUh?=
SK-HEP-1 M370PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XFOGlEPTB;M{iuO|gzOiEQvF2= NEDuNnRUSU6JRWK=
BPH-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnLdFJDUUN3ME2zPE45OzJ7IN88US=> M4PuNHNCVkeHUh?=
NCI-H1755 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrWTWM2OD1|OT61PFE4KM7:TR?= MnPKV2FPT0WU
LXF-289 NG\EO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXDU4hKSzVyPUO5MlgxQDRizszN MYjTRW5ITVJ?
SW1088 NXfYRZNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFznN3dKSzVyPUSwMlIyODdizszN Mk\nV2FPT0WU
MOLT-4 NWnZTGIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjGVJNKUUN3ME20NE4zQTBzIN88US=> Ml6zV2FPT0WU
AsPC-1 M2TVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTRyLkS1PFMh|ryP M4fqNnNCVkeHUh?=
HOP-62 NWfVdYloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\2TWM2OD12MD62OVY5KM7:TR?= NFjkWo5USU6JRWK=
A172 M2rmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\YfoxSUUN3ME20NE45PTFzIN88US=> NXTVOlg2W0GQR1XS
SN12C MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTRyLkmzPFUh|ryP NH;jOlNUSU6JRWK=
MDA-MB-231 NV\aTmxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn3TWM2OD12MD65PFk5KM7:TR?= NED5eHBUSU6JRWK=
RPMI-2650 M2\4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XmVWlEPTB;NEGuNVU6OyEQvF2= NHnNOFlUSU6JRWK=
KYSE-140 NIfKc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[2TWM2OD12MT64NVI{KM7:TR?= MkDQV2FPT0WU
KINGS-1 NHXMT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P0bGlEPTB;NEKuOFY6PyEQvF2= MlLZV2FPT0WU
HSC-3 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrXT5dKSzVyPUSyMlY3PjFizszN NEjpflRUSU6JRWK=
PC-14 Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfYfXVKSzVyPUSzMlE5QDJizszN NHjEemJUSU6JRWK=
COR-L105 M1\POmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrCSmpKSzVyPUSzMlY2ODJizszN NVfhblA6W0GQR1XS
BE-13 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHCV|YzUUN3ME20OE4zOzdzIN88US=> MXzTRW5ITVJ?
NCI-H661 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG3NWVKSzVyPUS0MlI6PThizszN M3\UZXNCVkeHUh?=
IST-MEL1 NYH4d45DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTR2LkO1PVkh|ryP M1\Bc3NCVkeHUh?=
HCC1806 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[5PGh4UUN3ME20OE42QDd|IN88US=> NV73PG9VW0GQR1XS
COLO-800 MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTR2Lki0OVMh|ryP NHL4[WxUSU6JRWK=
IST-SL2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnXSHdKSzVyPUS1MlEzPDdizszN M4rSeXNCVkeHUh?=
8305C NU\xfI56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\vVnVWUUN3ME20OU4{ODlizszN MUnTRW5ITVJ?
UACC-62 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTR4LkK4O|Uh|ryP NIfjcGtUSU6JRWK=
COR-L23 M1vrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTR5LkG5PUDPxE1? M{jwfHNCVkeHUh?=
EFE-184 NWDFO3hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WyRmlEPTB;NEeuN|g5KM7:TR?= NVnXTll5W0GQR1XS
DMS-114 NHvndWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF32c5BKSzVyPUS3MlQyPDlizszN MnS3V2FPT0WU
KYSE-520 MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7LdFNKSzVyPUS4MlU{OTVizszN NEjwc|VUSU6JRWK=
SNG-M MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTR7LkSzOEDPxE1? MWrTRW5ITVJ?
A2058 Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[4b2lEPTB;NEmuOFg5PSEQvF2= MVTTRW5ITVJ?

... Click to View More Cell Line Experimental Data
体内研究 OSI-906 作用于IGF-IR驱动的移植瘤鼠模型，抑制肿瘤生长，按 75 mg / kg剂量处理，导致100% TGI和 55% 衰退，按25 mg/kg剂量处理，导致 60% TGI，没有衰退。OSI-906处理犬，大鼠和小鼠，诱导不同的消除半衰期，消除半衰期分别为1.18 小时, 2.64小时 和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠，每天一次，Vmax值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天，提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型，在4 和24小时间最大程度抑制IGF-IR磷酸化(80%)，血浆药物浓度为26.6-4.77 μM。[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠，处理2，4，24小时，抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型，抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[1]
+ 展开

蛋白激酶生化实验:

通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中，使用聚 (Glu:Tyr)作为底物，结合到96孔实验板表面，使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物，通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中，人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白，且在内部纯化。通过抑制百分数对log10药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验，除非另有说明，取三次测量的最小值。
细胞实验：[1]
+ 展开
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3天
  • Method: 为了测定细胞增殖，细胞接种在含FCS 10%的合适培养基上，在不同浓度OSI-906存在时，温育3天。通过细胞内ATP含量的荧光量化，使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分，通过在不同浓度 OSI-906存在时的细胞密度除以对照组（只用DMSO处理）细胞密度。
    (Only for Reference)
动物实验：[1]
+ 展开
  • Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型
  • Formulation: 25 mM 酒石酸
  • Dosages: 25 mg/kg和75 mg/kg
  • Administration: 口服处理，每天一次，持续14天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
30% PEG 400+0.5% Tween 80+5% Propylene glycol 		30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.49
化学式

C26H23N5O
CAS号 867160-71-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答：

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

Selleck产品目录册

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

  • 泛IGF-1R抑制剂

    GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.

  • 活性最高的IGF-1R抑制剂

    BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.

  • 用于临床的IGF-1R抑制剂

    BMS-754807 : Phase II for Breast Cancer.

  • 最新的IGF-1R抑制剂

    PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

相关IGF-1R产品

  • Picropodophyllin (PPP) New

    Picropodophyllin (PPP)是一种选择性IGF-1R抑制剂，IC50为1 nM。它对IGF-IR具有高选择性，对IR的酪氨酸磷酸化或FGF-R、PDGF-R、EGF-R没有抑制作用。

  • Erlotinib New

    Erlotinib 是一种EGFR抑制剂，IC50 为 2 nM，对EGFR的敏感性比对人c-Src 或 v-Ab高1000多倍。

  • R428 (BGB324|Bemcentinib) New

    R428 (BGB324)是一种Axl抑制剂，IC50为14 nM，作用于Axl比作用于Abl选择性高100倍以上。作用于Axl选择性也比作用于Mer和Tyro3(高50到100倍)及InsR， EGFR， HER2，和PDGFRβ(高100倍以上)高。

  • BMS-536924

    BMS-536924是一种ATP竞争性的IGF-1R抑制剂，IC50为100 nM，对Mek， Fak，和Lck也具有适中的抑制活性，但对Akt1，和MAPK1/2几乎无抑制活性。

  • NVP-AEW541

    NVP-AEW541是一种有效的IGF-1R/InsR抑制剂，在无细胞试验中IC50为150 nM/140 nM，在细胞试验中对IGF-1R具有较高的作用和选择性。

  • NVP-ADW742

    NVP-ADW742是一种IGF-1R抑制剂，IC50为0.17 μM，作用于IGF-1R比作用于InsR效果强16倍以上；对HER2， PDGFR， VEGFR-2， Bcr-Abl和c-Kit几乎没有活性。

  • GSK1904529A

    GSK1904529A是一种选择性的IGF-1R和IR抑制剂，无细胞试验中IC50分别为27 nM和25 nM，作用于IGF-1R/InsR比作用于Akt1/2/， Aurora A/B，B-Raf， CDK2， EGFR等选择性高100倍以上。

  • BMS-754807

    BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂，在无细胞试验中IC50为1.8 nM/1.7 nM，对Met，Aurora A/B，TrkA/B和Ron作用稍弱，对Flt3， Lck，MK2，PKA，PKC等几乎没有抑制活性。Phase 2。

    Features:胰岛素样生长因子-1R/IR家族激酶的多重抑制剂

  • AG-1024

    AG-1024 抑制IGF-1R自磷酸化，IC50为7 μM，对IR作用效果稍弱，IC50为57 μM，且特异性区分InsR和IGF-1R（相比于其他酪氨酸磷酸化抑制剂）。

  • PQ 401

    PQ 401抑制IGF-1R区域自磷酸化，IC50为低于1 μM。

Tags: 购买Linsitinib (OSI-906) | Linsitinib (OSI-906)供应商 | 采购Linsitinib (OSI-906) | Linsitinib (OSI-906)价格 | Linsitinib (OSI-906)生产 | 订购Linsitinib (OSI-906) | Linsitinib (OSI-906)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID